On Monday, First Horizon National Corp (NYSE:FHN)’s shares declined -0.75% to $14.65.
First Horizon National Corp (FHN) board of directors has approved payment of a quarterly cash dividend on its common stock of $.06 per share. The dividend is payable on July 1, 2015, to the common shareholders of record on June 12, 2015.
The board of directors has also approved payment of a quarterly cash dividend of $1,550.00 per share on FHN’s Non-Cumulative Perpetual Preferred Stock, Series A (“Series A Preferred Stock”). This equates to a cash dividend of $0.387500 per Depositary Share (NYSE:FHN PrA), which each represent a 1/4000th interest in a share of the Series A Preferred Stock. The dividend is payable on July 10, 2015, to shareholders of record on June 25, 2015.
First Horizon National Corporation operates as the bank holding company for First Tennessee Bank National Association that provides various financial services in the United States and internationally.
Curis, Inc. (NASDAQ:CRIS)’s shares dropped -1.78% to $3.31.
Curis, Inc. (CRIS) declared results from the accomplished dose escalation and ongoing expansion stages of a Phase 1 trial of CUDC-907, an oral dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes. Data were presented at the Annual Meeting of American Society of Clinical Oncology (ASCO) that is being held in Chicago, IL. At the recommended Phase 2 dose and plan, CUDC-907 has demonstrated evidence of clinical activity with objective responses observed in patients with relapsed/ refractory diffuse large B cell lymphoma (DLBCL) and Hodgkin’s lymphoma (HL). Two complete responses (CRs) and 4 partial responses (PRs) were stated in 10 response evaluable patients with DLBCL, counting 3 responses (1 CR and 2 PRs) in patients with transformed follicular lymphoma (t-FL/DLBCL), a very difficult to treat subset of DLBCL. One patient with HL practiced partial response out of a total of 12 response evaluable patients with HL. In addition, stable disease (SD) has been observed in 25 of 44 response evaluable patients across various lymphomas and multiple myeloma (MM).
The Phase 1 dose escalation and expansion study was designed to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose, in addition to preliminary anti-cancer activity of oral CUDC-907 in patients with relapsed/ refractory lymphoma or MM. As of the April 27, 2015 data cut-off for the ASCO presentation, a total of 57 patients had been enrolled in the study, with 40 and 17 patients in the dose escalation and expansion phases of the study, respectively. In the accomplished dose escalation phase, patients either received CUDC-907 daily (QD, doses: 30 or 60 mg), or intermittently on twice weekly (BIW) or thrice weekly (TIW) plans (daily doses: 60, 90, 120 or 150 mg), or on a 5 days on, 2 days off (5/2) plan (dose:60 mg). In the ongoing expansion phase, patients either receive CUDC-907 60 mg on the 5/2 plan or 120 mg on the TIW plan.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase I clinical trials for advanced lymphomas and multiple myeloma; and HER 2-/ ER+ or PR+ breast cancer, and NUT midline carcinoma.
At the end of Monday’s trade, Delphi Automotive PLC (NYSE:DLPH)‘s shares dipped -0.17% to $86.83.
Delphi Automotive PLC (DLPH) a leading global vehicle components manufacturer, recently stated first quarter 2015 U.S. GAAP earnings from ongoing operations of $0.99 per diluted share. Not taking into account special items, first quarter earnings from ongoing operations raised 4% to $1.21 per diluted share.
Highlights Comprise:
- Revenue of $3.8 billion, up 6% adjusted for currency exchange and commodity movements.
- Growth of 4 points above market.
- S. GAAP diluted earnings per share from ongoing operations of $0.99.
- Not taking into account special items, earnings from ongoing operations of $1.21 per diluted share, up 4%.
- Adjusted Operating Income of $472 million, up 2%.
- Adjusted Operating Income margin of 12.4%, up 50 basis points.
- Generated $121 million of cash from ongoing operations.
- Share repurchases and dividends of $313 million.
- Declared agreement for sale of Thermal Systems business to MAHLE for about $727 million, predictable to close in the 3rd quarter of 2015.
- Thermal Systems classified as suspended operations for all periods presented.
First Quarter 2015 Results
The Company stated first quarter 2015 revenue of $3.8 billion, a decline of 3% from the prior year period, reflecting unfavorable currency impacts, which offset continued volume growth in Asia and North America. Adjusted for the impacts of currency exchange and commodity movements, revenue raised by 6% in the first quarter. This reflects growth of 15% in Asia, 7% in North America and 2% in Europe, partially offset by a decline of 16% in South America.
Delphi Automotive PLC, together with its auxiliaries, manufacturers vehicle components; and provides electrical and electronic, powertrain, safety, and thermal technology solutions to the automotive and commercial vehicle markets worldwide.
Deckers Outdoor Corp (NYSE:DECK), ended its Monday’s trading session with 0.22% gain, and closed at $68.30.
Deckers Outdoor Corp (DECK) declared financial results for the fourth fiscal quarter and fiscal year ended March 31, 2015.
Fourth Quarter Fiscal 2015 Financial Review
- Net sales raised 15.6% to a record $340.6 million contrast to $294.7 million for the same period last year. On a constant currency basis, net sales raised 19.1%.
- Gross margin was 44.7% contrast to 48.9% for the same period last year.
- SG&A expenses as a percentage of sales were 44.5% contrast to 49.1% for the same period last year.
- Diluted earnings per share was $0.04 contrast to a diluted loss per share of $(0.08) for the same period last year.
Brand Summary
- UGG® brand net sales for the fourth quarter raised 9.7% to $216.8 million contrast to $197.6 million for the same period last year. The enhance in sales was driven by an enhance in global wholesale and distributor sales, higher global E-Commerce sales, sales contributions from new worldwide retail store openings, partially offset by a decrease in same store sales. For fiscal 2015, UGG brand sales raised 12.6% to $1.49 billion.
- Teva® brand net sales for the fourth quarter raised 13.4% to $53.1 million contrast to $46.8 million for the same period last year. The enhance in sales was driven by an enhance in international wholesale and distributor sales, partially offset by a decrease in domestic wholesale sales. For fiscal 2015, Teva brand sales raised 13.5% to $126.7 million.
Deckers Outdoor Corporation designs, markets, and distributes footwear, apparel, and accessories for outdoor activities and casual lifestyle use for men, women, and children. The company offers luxurious comfort footwear, handbags, apparel, and cold weather accessories under the UGG brand name; sandals, shoes, boots, and amphibious footwear under Teva brand name; and action sport footwear under the Sanuk brand name.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
